SIC
PRME icon

SJS Investment Consulting’s Prime Medicine PRME Stock Holding History

SJS Investment Consulting’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10
Closed -$35 – 2965
2026
Q1 		$35 Buy
+10
New +$38 ﹤0.01% 2299

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
ACM
Alessandra Capital Management Torrance, California $141M AUM
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

SJS Investment Consulting's PRME Position: Q2 2026 in Review

SJS Investment Consulting sold out of Prime Medicine (PRME) in Q2 2026, closing a stake of 10 shares — an estimated $35 sold.

SJS Investment Consulting first reported a position in PRME in Q1 2026 and held it in 1 quarter. The position peaked at $35 in Q1 2026. 82 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • SJS Investment Consulting reported no remaining Prime Medicine position as of Q2 2026 after selling out during the quarter.
  • SJS Investment Consulting sold 10 Prime Medicine shares in Q2 2026, an estimated $35.
  • SJS Investment Consulting first reported a position in Prime Medicine in Q1 2026 and held it in 1 quarter.
  • SJS Investment Consulting's Prime Medicine position peaked at $35 in Q1 2026.
  • 82 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.